{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:45:49Z","timestamp":1792215949948,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clbc.2026.08.013","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:44:59Z","timestamp":1787438699000},"page":"52-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-7984","authenticated-orcid":false,"given":"Akihiro","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakako","family":"Inohana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Nakame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Nukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yokogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.08.013_bib0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2026.08.013_bib0002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032969","article-title":"Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review","volume":"24","author":"van den Ende","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2026.08.013_bib0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","article-title":"A comprehensive immunologic portrait of triple-negative breast cancer","volume":"11","author":"Liu","year":"2018","journal-title":"Transl Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0006","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.08.013_bib0007","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.08.013_bib0008","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1245\/s10434-024-16390-7","article-title":"Real-world outcomes with the KEYNOTE-522 regimen in early-stage triple-negative breast cancer","volume":"32","author":"Connors","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-017-4499-7","article-title":"Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer","volume":"167","author":"Leon-Ferre","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.08.013_bib0010","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group","volume":"7","author":"El Bairi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2026.08.013_bib0011","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0012","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/modpathol.2016.109","article-title":"Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group","volume":"29","author":"Denkert","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0013","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/0284186X.2017.1403040","article-title":"Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists","volume":"57","author":"Tramm","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0014","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","article-title":"High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin\u2014but not with treatment of physician's choice\u2014in the EMBRACE study","volume":"27","author":"Miyoshi","year":"2020","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2026.08.013_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3892\/mco.2024.2713","article-title":"Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood-based parameters and ratio","volume":"20","author":"Shimada","year":"2024","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0016","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1245\/s10434-015-4934-0","article-title":"Predictive value of neutrophil\/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer","volume":"23","author":"Asano","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153459","article-title":"Platelet-lymphocyte ratio as a useful predictor of the therapeutic effect of neoadjuvant chemotherapy in breast cancer","volume":"11","author":"Asano","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2026.08.013_bib0018","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12885-015-1204-2","article-title":"Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients","volume":"15","author":"Pistelli","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2026.08.013_bib0019","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio for patients with triple-negative breast cancer: a meta-analysis","volume":"101","author":"Liu","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clbc.2026.08.013_bib0020","article-title":"The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy","volume":"12","author":"Gao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678315","article-title":"Platelet-to-lymphocyte ratio is associated with favorable response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients","volume":"11","author":"Lusho","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0022","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1016\/j.clbc.2021.04.004","article-title":"Relationship between the neutrophil to lymphocyte ratio, stromal tumor-infiltrating lymphocytes, and the prognosis and response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"21","author":"Pang","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2026.08.013_bib0023","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000509498","article-title":"Prognostic roles of neutrophil-to-lymphocyte ratio and stromal tumor-infiltrating lymphocytes and their relationship in locally advanced triple-negative breast cancer treated with neoadjuvant chemotherapy","volume":"16","author":"Dong","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.clbc.2026.08.013_bib0024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13058-022-01563-7","article-title":"High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs","volume":"24","author":"Onagi","year":"2022","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2026.08.013_bib0025","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s12282-023-01504-y","article-title":"Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer","volume":"30","author":"Kusama","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2026.08.013_bib0026","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0027","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0028","doi-asserted-by":"crossref","first-page":"415","DOI":"10.21037\/gs-23-80","article-title":"Neutrophil-to-lymphocyte ratio is a negative prognostic biomarker for luminal A breast cancer","volume":"12","author":"Xiang","year":"2023","journal-title":"Gland Surg"},{"key":"10.1016\/j.clbc.2026.08.013_bib0029","first-page":"1432","article-title":"Predicting the role of the pretreatment neutrophil to lymphocyte ratio in the survival of early triple-negative breast cancer patients","volume":"20","author":"Bozkurt","year":"2015","journal-title":"J. BUON"},{"key":"10.1016\/j.clbc.2026.08.013_bib0030","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.21873\/anticanres.17323","article-title":"Comparison of the predictive and prognostic capacities of neutrophil, lymphocyte and platelet counts and tumor-infiltrating lymphocytes in triple-negative breast cancer: preliminary results of the PERCEPTION study","volume":"44","author":"Giro","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2026.08.013_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-074874","article-title":"Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis","volume":"13","author":"Qi","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.clbc.2026.08.013_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1677929","article-title":"Association between tumor-infiltrating lymphocytes and oncotype DX estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 single gene scores in hormone receptor-positive\/HER2-negative breast cancer","volume":"16","author":"Ohara","year":"2026","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0033","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jso.24275","article-title":"No effect of tumor-infiltrating lymphocytes (TILs) on prognosis in patients with early triple-negative breast cancer: Validation of recommendations by the International TILs Working Group 2014","volume":"114","author":"Park","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0034","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/pin.13510","article-title":"Combined use of immunoreactivities of Efp and ZCCHC3 for predicting prognosis of patients with triple-negative breast cancer","volume":"75","author":"Fujimoto","year":"2025","journal-title":"Pathol Int"},{"key":"10.1016\/j.clbc.2026.08.013_bib0035","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2025.2034","article-title":"Neutrophil-to-lymphocyte ratio predicts long-term survival in early triple negative breast cancer treated with neoadjuvant chemotherapy","volume":"19","author":"Polho","year":"2025","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.clbc.2026.08.013_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154687","article-title":"Tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in relation to pathological complete remission to neoadjuvant therapy and prognosis in triple negative breast cancer","volume":"248","author":"Zhao","year":"2023","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.clbc.2026.08.013_bib0037","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13402-025-01129-7","article-title":"Platelets in the tumor microenvironment: potential mediators of immune exclusion and resistance to immune checkpoint inhibitor therapy","volume":"49","author":"Nasir Kansestani","year":"2026","journal-title":"Cell Oncol"},{"key":"10.1016\/j.clbc.2026.08.013_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188762","article-title":"Tumor-associated neutrophils and neutrophil-targeted cancer therapies","volume":"1877","author":"Que","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.clbc.2026.08.013_bib0039","article-title":"Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis","volume":"111","author":"Dowling","year":"2024","journal-title":"Br J Surg"},{"key":"10.1016\/j.clbc.2026.08.013_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133327","article-title":"Circulating and tumor-associated neutrophils in the era of immune checkpoint inhibitors: dynamics, phenotypes, metabolism, and functions","volume":"15","author":"Gibellini","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2026.08.013_bib0041","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41568-023-00639-6","article-title":"The dynamic role of platelets in cancer progression and their therapeutic implications","volume":"24","author":"Li","year":"2024","journal-title":"Nat Rev Cancer"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:31:11Z","timestamp":1792215071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1526820926001515"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.08.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}